The stock of InVitae Corp (NYSE:NVTA) is a huge mover today! About 125,712 shares traded hands or 125.72% up from the average. InVitae Corp (NYSE:NVTA) has declined 23.76% since March 29, 2016 and is downtrending. It has underperformed by 27.23% the S&P500.
The move comes after 9 months positive chart setup for the $254.60M company. It was reported on Oct, 31 by Barchart.com. We have $21.75 PT which if reached, will make NYSE:NVTA worth $448.10 million more.
Analysts await InVitae Corp (NYSE:NVTA) to report earnings on November, 3. They expect $-0.65 earnings per share, up 8.45% or $0.06 from last year’s $-0.71 per share. After $-0.77 actual earnings per share reported by InVitae Corp for the previous quarter, Wall Street now forecasts -15.58% EPS growth.
InVitae Corp (NYSE:NVTA) Ratings Coverage
Out of 3 analysts covering Invitae (NYSE:NVTA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Invitae has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. As per Friday, August 14, the company rating was initiated by William Blair. As per Thursday, January 28, the company rating was downgraded by Leerink Swann. JP Morgan maintained InVitae Corp (NYSE:NVTA) on Tuesday, August 9 with “Overweight” rating.
According to Zacks Investment Research, “Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.”
More notable recent InVitae Corp (NYSE:NVTA) news were published by: Bizjournals.com which released: “EXCLUSIVE: DNA testing giant leases entire Potrero Hill redevelopment site” on September 22, 2015, also Seekingalpha.com with their article: “Invitae Corporation: Moving To Equity Dilution Or Insolvency” published on October 23, 2015, Businesswire.com published: “Invitae Contributes More Than 10000 Additional Genetic Variants to the ClinVar …” on June 28, 2016. More interesting news about InVitae Corp (NYSE:NVTA) were released by: Bizjournals.com and their article: “Genetic testing firm Invitae seeks IPO of $86 million (Video)” published on January 10, 2015 as well as Streetinsider.com‘s news article titled: “Form 8-K Invitae Corp For: Oct 13” with publication date: October 13, 2016.
NVTA Company Profile
Invitae Corporation (Invitae), incorporated on January 13, 2010, utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.